Abstract
This chapter is focusing on the most exciting nuclear procedure: the metabolic investigation of positron emission tomography and fusion images with computed tomography.
The chapter underlines the utility of the method in the primary diagnosis of endocrinology diseases and in the follow-up of different endocrine tumors. The metabolic F-18-fluoro-2-deoxy-d-glucose has already been accepted as an essential tool in staging, re-staging, and therapy response assessment of many tumors. The use of PET/CT fusion scanners has been demonstrated to significantly increase accuracy of lesion detection, combining the high anatomical definition of CT with the high sensitivity of PET.
The chapter describes techniques, procedures useful in endocrine practice and has a part of clinical cases, interesting images, and key points.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Bertagna F, Bosio G, Biasiotto G et al (2009) A- F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med 34(11):756–761
Bogsrud TV, Karantanis D, Nathan MA et al (2007) The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 28:373–381
Chin BB, Patel P, Cohade C et al (2004) Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metabol 89:91–95
Choi JY, Lee KS, Kim HJ et al (2006) Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 47:609–615
deGroot JW, Links TP, Jager PL (2004) Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11:786–794
Kang KW, Kim SK, Kang HS et al (2003) Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88:4100–4104
McDougall IR, Davidson J, Segall GM (2001) Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun 22(5):485–492
Nahas Z, Goldenberg D, Fakhry C et al (2005) The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115:237–243
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Thyroid carcinoma. V.3 (2011) National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf. Accessed 25/10/2011
Palmedo H, Bucerius J, Joe A et al (2006) Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47(4):616–624
Petrich T, Borner AR, Otto D et al (2002) Influence of rhTSH on [(18)F] fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 29(5):641–647
Piciu D, Irimie A, Duncea I et al (2010) Positron emission tomography – computer tomography fusion image, with 18-fluoro-2-deoxyD-glucose in the follow-up of patients with differentiated thyroid carcinoma. Acta Endocrinol (Buc) 6:15–26. doi:10.4183/aeb.2010.15
Robbins RJ, Wan Q, Grewal RK et al (2006) Real-time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning. J Clin Endocrinol Metab 91:498–505
Sandeep TC, Strachan MW, Reynolds RM et al (2006) Second primary cancers in thyroid cancer patients: A multinational record linkage study. J Clin Endocrinol Metab 91:1819–1825
Schluter B, Bohuslavizki KH, Beyer W et al (2001) Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131- I scan. J Nucl Med 42(1):71–76
Seong Bae J, Chae BJ, Park CW et al (2009) Incidental thyroid lesions detected by FDG PET/CT: prevalence and risk of thyroid cancer. World J Surg Oncol 7(1):63–69
The American Thyroid Association (ATA). Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer (2009) Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 19(11):1195–1214
Verkooijen RB, Smit JW, Romijn JA et al (2006) The incidence of second primary tumours in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 155:801–806
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2012 Springer-Verlag GmbH Berlin Heidelberg
About this chapter
Cite this chapter
Piciu, D. (2012). PET/CT in Endocrinology. In: Nuclear Endocrinology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-25014-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-25014-9_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-25013-2
Online ISBN: 978-3-642-25014-9
eBook Packages: MedicineMedicine (R0)